Our findings of DHME’s inhibitory action on both STAT3 and WNT/β-catenin signaling axes, two fundamental signaling axes involved in CRC genesis and progression, underpin DHME as a potential agent for CRC chemotherapy. The gene discussed is STAT3; the disease is colorectal carcinoma.